Description: Experts argue LLMs won’t be the end-state: new architectures (multimodal, agentic, beyond transformers) will ...
It only takes 250 bad files to wreck an AI model, and now anyone can do it. To stay safe, you need to treat your data pipeline like a high-security zone.
Find the best AI search visibility tools for enterprises using a tested framework: prompt volume, model coverage, source ...
MIT researchers unveil a new fine-tuning method that lets enterprises consolidate their "model zoos" into a single, continuously learning agent.
Semantic brand equity ensures LLMs and AI search engines recommend your business. Our guide reveals how AI perceives and ranks your brand.
Opinion
3dOpinion
The Real Truth About The Upsides And Downsides Of Generative AI As A Mental Health Advisor
Most discussions about AI that's used for mental health is tilted to one side or the other, either its good or its bad. The full story is a tradeoff. An AI Insider scoop.
Abstract: With the global rise of large language models (LLMs) in English as a foreign language (EFL) education, understanding learners’ perceptions and emotions is crucial, especially for AIED ...
Methods: Using the CrowdTangle application programming interface, we collected and processed 243,029 English-language and 96,334 Spanish-language Facebook posts. We applied BERTopic with the ...
PolyCouncil is an open-source application that orchestrates multiple local Large Language Models (LLMs) running in LM Studio. Instead of querying a single model, PolyCouncil runs multiple models in ...
Katelyn is a writer with CNET covering artificial intelligence, including chatbots, image and video generators. Her work explores how new AI technology is infiltrating our lives, shaping the content ...
Large language models (LLMs), with their advanced natural language processing capabilities, offer potential as innovative tools to facilitate evidence dissemination. However, general-purpose LLMs ...
1910 is on a mission to “make undruggable targets a thing of the past” by “turning every pharma company into an AI company,” says founder and CEO, Jen Asher, PhD. The Sam Altman–backed AI drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results